- Home
- LNKB vs PBYI Comparison
LNKB vs PBYI Comparison
Compare LNKB & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- PBYI
- Stock Information
- Founded
- LNKB 2018
- PBYI 2010
- Country
- LNKB United States
- PBYI United States
- Employees
- LNKB N/A
- PBYI N/A
- Industry
- LNKB
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- LNKB
- PBYI Health Care
- Exchange
- LNKB Nasdaq
- PBYI Nasdaq
- Market Cap
- LNKB 261.4M
- PBYI 263.4M
- IPO Year
- LNKB N/A
- PBYI N/A
- Fundamental
- Price
- LNKB $6.99
- PBYI $5.25
- Analyst Decision
- LNKB Strong Buy
- PBYI Strong Buy
- Analyst Count
- LNKB 1
- PBYI 1
- Target Price
- LNKB $9.00
- PBYI $7.00
- AVG Volume (30 Days)
- LNKB 109.7K
- PBYI 434.6K
- Earning Date
- LNKB 10-27-2025
- PBYI 11-06-2025
- Dividend Yield
- LNKB 4.29%
- PBYI N/A
- EPS Growth
- LNKB 512.12
- PBYI 434.29
- EPS
- LNKB 1.03
- PBYI 0.97
- Revenue
- LNKB $122,594,000.00
- PBYI $238,062,000.00
- Revenue This Year
- LNKB $18.26
- PBYI N/A
- Revenue Next Year
- LNKB N/A
- PBYI N/A
- P/E Ratio
- LNKB $6.80
- PBYI $5.40
- Revenue Growth
- LNKB 42.32
- PBYI 8.63
- 52 Week Low
- LNKB $6.09
- PBYI $2.32
- 52 Week High
- LNKB $7.98
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- LNKB 46.73
- PBYI 55.72
- Support Level
- LNKB $6.85
- PBYI $5.00
- Resistance Level
- LNKB $7.16
- PBYI $5.61
- Average True Range (ATR)
- LNKB 0.19
- PBYI 0.26
- MACD
- LNKB -0.01
- PBYI -0.03
- Stochastic Oscillator
- LNKB 26.42
- PBYI 33.33
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.